Reading RDNT? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track RDNT free→Reading RDNT? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track RDNT free→NASDAQHealth CareDiagnostics & ResearchSnapshot 2026-06-16
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
Recent financial performance is strong, but the company was unprofitable over the past year, so its earnings quality can't be assessed. Management's recent track record has been fairly steady, and risk is moderate. The sector backdrop is a headwind, and compared with sector peers, RDNT is below typical. Peer multiples imply a price about 75% below where it trades (it looks expensive on this basis); the read is expensive, growth-justified, as it is rich on today's multiple, but the three-year horizon reads cheaper once expected earnings growth is included. The read is provisional.
Daily closes. Earnings/event dots are placed inline.
A consensus fair price across 6 valuation methods, at three horizons. Current price $56.51. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
No-growth: today's peer multiple on trailing earnings. The headline read.
Embeds projected growth. Leans optimistic by design. Upside context.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $57 RDNT trades at 2× p/s, below its 2× p/s peer median. Our $32 fair value sits above the price; medium confidence. Not investment advice.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
The market is pricing in roughly 80% near-term growth, well above our forecast of about 14%. This describes what's priced in, not a forecast of the move.
Flags: expensive valuation, a turbulent sector regime (Heating).
For similar setups historically (n=2,301): about 43% saw a 20%+ drawdown, and roughly 77% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated strong grew net income 59% of the time over the next year (vs 52% for the rest of the cohort, n=2344).
Over the trailing year it converted -23.70x of net income into operating cash flow.
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, long-term interest rates, Fed net liquidity, real (inflation-adjusted) rates.
5 material management or governance events in the past 24 months, led by capital-allocation actions. Historically, Health Care names rated neutral grew net income 58% of the time over the next year (vs 50% for the rest of the cohort, n=842).
The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.
EPS estimate $0.00 → $0.20. 3 raised, 3 cut, 6 covering analysts.
0 upgrades, 0 downgrades / 30d, 1 maintained. 100% of analysts rate Buy.
1 PT revisions / 30d. Avg target 21.8% above current price.
0 positive, 1 negative / 30d. See F4 management tile for the event list.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
What a normal day, a bad day, and the worst of the last year would mean for a $10,000 position.
On a typical day, $10k can swing ±$160.
How much price usually moves either way.
On a bad day, this stock has moved -$432.
A rough but not unusual down day (about the 95th percentile).
In the worst 12 months, $10k could have lost $3,860.
Deepest peak-to-trough drop in the last year.
Past results, not a forecast. Not investment advice.
The most important moves since the prior daily snapshot.
No material changes since the prior snapshot.
as of 2026-06-16
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Why it matters: Acquisitions could boost revenue and support growth. This aligns with management's top priority.
Confirms:A new acquisition could bring in over $50 million each year.
Disproves:No acquisitions announced in the next quarter.
Recent news graded against this company's own objectives — whether it reinforces or challenges the thesis, and how confirmed it is.
No graded news catalysts for RDNT yet.
Conditional scenarios: if X happens, the view would shift in this direction. These are not predictions.
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
Entry into a Material Definitive Agreement. On June 10, 2026, RadNet, Inc. (the “ Company ”) and the Company’s wholly-owned subsidiary, Radnet Management, Inc. (the “ Borrower ”), entered into Incremental Amendment No. 3 to Credit and Guaranty Agreement (the “ Third Amendment ”) with the lenders and financial institutions named therein (collectively, the “ Lenders ”), Barclays Bank PLC, as administrative agent and collateral agent on behalf of the lenders, and substantially all of the Company…
Whether the overall read has been drifting up or down lately, and how it's changed since last week.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Long-thesis check; widest uncertainty.
Looks more expensive than peers.
Richer than its own typical valuation.
Trailing four: 2025-Q1, 2025-Q2, 2025-Q3, 2026-Q1
A side-by-side read on sector standing, valuation, and risk versus Health Care Services.
| Stock | Sector standing | Valuation | Risk |
|---|---|---|---|
RDNT RadNet, Inc. | Below typical Show detailsSector percentile: 11 of 100 | expensive | moderate |
CVS CVS Health | Typical Show detailsSector percentile: 64 of 100 | fair | moderate |
CI Cigna | Above typical Show detailsSector percentile: 92 of 100 | inexpensive | moderate |
DGX Quest Diagnostics | Above typical Show detailsSector percentile: 73 of 100 | fair | moderate |
LH Labcorp | Above typical Show detailsSector percentile: 80 of 100 | fair | moderate |
Not investment advice. As of 2026-06-16.
via XLV
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive. Historically, headwind regimes have averaged stronger forward returns than tailwind.
Context label only: describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.
Not investment advice. As of 2026-06-16.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Continue to grow revenue by acquiring strategic assets and businesses.
Focus on improving cash flow through operational efficiencies and strategic initiatives.
Aim to enhance operating income through cost management and revenue growth.
Why it matters: Strong revenue growth shows RadNet is doing well. This also helps cash flow.
Confirms:Q2 2026 revenue was over $690 million. This shows more than 20% growth from last year.
Disproves:Q2 2026 revenue was below $690 million. This shows growth under 20% from last year.
Why it matters: The earnings results will show if revenue growth continues or slows. This is key for future performance.
Confirms one read:Q2 earnings report shows revenue growth above 10% year over year.
Confirms the other:Q2 earnings report shows revenue growth below 5% year over year.
Why it matters: Better operating income is key for RadNet's long-term profits. It shows better cost control.
Confirms:Operating income is trending up, above the current score of 27.9%.
Disproves:Operating income is flat or falling, keeping the score below 27.9%.
Why it matters: More cash flow helps the company’s finances and operations. Management pays attention to this.
Confirms:Cash flow from operations increases by 15% or more in the next quarter.
Disproves:Cash flow from operations declines or remains flat in the next quarter.
Why it matters: The joint venture with Trinity Health could enhance RadNet's market position and revenue streams.
Confirms one read:The joint venture added positive revenue in Q3 2026 results.
Confirms the other:The joint venture did not add significant revenue in Q3 2026 results.
Why it matters: Cash flow growth shows RadNet's ability to manage working capital. It affects future investments.
Confirms:Cash from operations increases to over $80M in Q2.
Disproves:Cash from operations falls below $70M in Q2.
Why it matters: Better operating income is key for RadNet's finances. It shows they manage costs well.
Confirms:Operating income improves to above -$10M in Q2.
Disproves:Operating income remains below -$20M in Q2.
Why it matters: Higher operating income is key for making money over time. Management views this as a mixed priority.
Confirms one read:Operating income increases by 10% or more in the next quarter.
Confirms the other:Operating income decreases or remains flat in the next quarter.
Why it matters: Changes in sector growth can affect RadNet's results. It shows the overall market situation.
Confirms one read:Sector revenue growth drops below 3% year over year.
Confirms the other:Sector revenue growth stays above 5% year over year.
Why it matters: Securing this loan would provide RadNet with funds for growth. It shows financial health and strategic planning.
Confirms:A press release confirmed the closing of the $200 million loan.
Disproves:No announcement or failure to secure the loan by the end of June 2026.
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The information set forth in
Other Events. On June 3, 2026, RadNet, Inc. issued a press release related to a proposed amendment to its Third Amended and Restated First Lien Credit and Guaranty Agreement for an incremental term loan in the aggregate principal amount of $200.0 million. A copy of this press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
RESULTS OF OPERATIONS AND FINANCIAL CONDITION On May 10, 2026 RadNet, Inc. (“RadNet”) issued a press release regarding its financial results for the first quarter ended March 31, 2026. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Current Report on Form 8-K, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange…
RESULTS OF OPERATIONS AND FINANCIAL CONDITION. On March 2, 2026 RadNet, Inc. (“RadNet”) issued a press release regarding its financial results for the fourth quarter ended December 31, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Current Report on Form 8-K, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Ex…